Wendy Dixon

Dr. Wendy Dixon has over 40 years of biopharmaceutical industry experience in drug development with leadership roles in regulatory affairs and commercial capabilities. Wendy currently serves on the Board of Directors of Alkermes plc, Incyte Corp., and Arvinas Inc. Previously, Wendy served on the Boards of Directors of bluebird bio, Inc., Dentsply International, Furiex Pharmaceuticals, Orexigen Therapeutics, Sesen Bio, Inc. (formerly Eleven Biotherapeutics, Inc.), Ardea Biosciences, Inc. and Voyager Therapeutics, Inc.

Wendy served as the Chief Marketing Officer and President of Global Marketing at Bristol Myers Squibb for eight years and as a Senior Vice President of Marketing at Merck for five years. Prior to that, she held various executive management positions at West Pharmaceuticals, Osteotech and Centocor, as well as various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist.

Wendy holds a Ph.D. in Biochemistry and an M.Sc. and B.Sc. in Natural Science from the University of Cambridge.